Literature DB >> 8871584

Acute motor axonal neuropathy: an antibody-mediated attack on axolemma.

C Hafer-Macko1, S T Hsieh, C Y Li, T W Ho, K Sheikh, D R Cornblath, G M McKhann, A K Asbury, J W Griffin.   

Abstract

The acute motor axonal neuropathy (AMAN) form of the Guillain-Barre syndrome is a paralytic disorder of abrupt onset characterized pathologically by motor nerve fiber degeneration of variable severity and by sparing of sensory fibers. There is little demyelination or lymphocytic inflammation. Most cases have antecedent infection with Campylobacter jejuni and many have antibodies directed toward GM1 ganglioside-like epitopes, but the mechanism of nerve-fiber injury has not been defined. In 7 fatal cases of AMAN, immunocytochemistry demonstrated the presence of IgG and the complement activation product C3d bound to the axolemma of motor fibers. The most frequently involved site was the nodal axolemma, but in more severe cases IgG and C3d were found within the periaxonal space of the myelinated internodes, bound to the outer surface of the motor axon. These results suggest that AMAN is a novel disorder caused by an antibody- and complement-mediated attack on the axolemma of motor fibers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871584     DOI: 10.1002/ana.410400414

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  81 in total

1.  Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy.

Authors:  M Nagamatsu; S Terao; K Misu; M Li; N Hattori; M Ichimura; M Sakai; H Yamamoto; H Watanabe; S Riku; E Ikeda; J Hata; M Oda; M Satake; N Nakamura; S Matsuya; Y Hashizume; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

2.  Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes.

Authors:  Nobuhiro Yuki; Norito Kokubun; Satoshi Kuwabara; Yukari Sekiguchi; Masafumi Ito; Masaaki Odaka; Koichi Hirata; Francesca Notturno; Antonino Uncini
Journal:  J Neurol       Date:  2011-12-06       Impact factor: 4.849

3.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

Review 4.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

5.  Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Authors:  Simon N Fewou; Angie Rupp; Lauren E Nickolay; Kathryn Carrick; Kay N Greenshields; John Pediani; Jaap J Plomp; Hugh J Willison
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 6.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 7.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

8.  Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

Authors:  Alberto Carmona; Juan Domingo Alonso; Manuel de las Heras; Agustín Navarrete
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

9.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

Review 10.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.